Mediterranean visceral leishmaniasis in immunocompetent children. Report of two cases relapsed after specific therapy;La leishmaniosi viscerale nel bambino immunocompetente. Descrizione di due casi di recidiva dopo terapia specifica

Infezioni in Medicina

Volumn 12, Issue 2, 2004, Pages 139-143

  Colomba, Claudia ^a   Scarlata, Francesco ^a   Salsa, Ludovico ^a   Polara, Valentina Frasca ^a   Titone, Lucina ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Children; Immunocompetent; Relapses; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; GLUCANTIN; MEGLUMINE ANTIMONATE;

ADOLESCENT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; DOG; ENDEMIC DISEASE; FEMALE; FEVER; FOLLOW UP; GREECE; HUMAN; IMMUNOCOMPETENCE; ITALY; LEISHMANIA INFANTUM; MALE; MICROSCOPY; MOROCCO; PHLEBOTOMUS; POLYMERASE CHAIN REACTION; PSYCHODIDAE; SCHOOL CHILD; SENSITIVITY ANALYSIS; SPAIN; SPLENOMEGALY; TUNISIA; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; BONE MARROW; FEMALE; HUMANS; IMMUNOCOMPETENCE; INFANT; LEISHMANIASIS, VISCERAL; LIPOSOMES; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PARASITEMIA; RECURRENCE;

EID: 3242741946     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. World Health Organization. Control of the leishmaniasis. Geneva, Switzerland: WHO, 1990. Technical Report Series No. 9793.
2. Murray H.W. Treatment of visceral leishmaniasis (Kala-azar): a decade of progress and future approaches. Int. J. Infect. Dis. 4, 158-177, 2000.
3. Cascio A., Gradoni L., Scarlata F. et al. Epidemiology surveillance of visceral leishmaniasis in Sicily, Italy. Am. J. Trop. Med. Hyg. 57, 75-78, 1997.
4. Cascio A., Colomba C., Antinori S. Pediatric visceral leishmaniasis in western Sicily, Italy: a retrospective analysis of 111 cases. Eur. J. Clin. Microbiol. Infect. Dis. 21, 277-282, 2002.
5. Lira R., Sundar S., Makharia A. et al. Evidence that the high incidence of treatment failure in Indian kalaazar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180, 564-567, 1999.
6. Meyeroff A. U.S. Food and Drug Administraion approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis. 28, 42-48, 1999.
7. di Martino L., Davidson R.N., Giacchino R. et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin-B. J. Pediatrics 131, 271-277, 1997.
8. Piarroux R., Gambarelli F., Dumon H., et al. Comparison of PCR with direct examination of bone marrow aspiration, myeloculture, and serology for diagnosis of visceral leishmaniasis in immunocompromised patients. J. Clin. Microbiol. 32, 746-749, 1994.
9. Lachaud L., Dereure J., Chabbert E. et al. Optimized PCR using patient blood samples for diagnosis and follow-up of visceral leishmaniasis, with special reference to AIDS patients. J. Clin. Microbiol. 38, 236-240, 2000.
10. Pizzuto M., Piazza M., Senese D., et al. Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1. J. Clin. Microbiol. 39, 357-361, 2001.
11. Minodier P., Piarroux R., Garnier J.M., et al. Pediatric visceral leishmaniasis in southern France. Pediatr. Infect. Dis. J. 17, 701-704, 1998.
12. Cascio A., Calattini S., Colomba C., et al. Polymerase Chain Reaction in the diagnosis and prognosis of Mediterranean visceral leishmaniasis in immunocompetent children. Pediatrics 109, (2) E-27, 2002.